Mavyret for HCV/HIV Coinfection and Genotype 3: A Report of Three Cases

Intern Med. 2018 Nov 19. doi: 10.2169/internalmedicine.1856-18.
[Epub ahead of print]

Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases
Takuya Sho1, Goki Suda1, Megumi Kimura1, Tomoe Shimazaki1, Osamu Maehara1, Taku Shigesawa1, Kazuharu Suzuki1, Akihisa Nakamura1, Masatsugu Ohara1, Machiko Umemura1, Takaaki Izumi1, Naoki Kawagishi1, Masaru Baba2, Masato Nakai1, Mitsuteru Natsuizka1, Kenichi Morikawa1, Koji Ogawa1 and Naoya Sakamoto1; for the NORTE Study Group

Abstract:
The efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with human immunodeficiency virus (HIV) and/or genotype 3 hepatitis C virus (HCV) infection is yet to be clarified. This is because no or only a few patients have been included in Japanese phase 3 trials. We herein report for the first time the successful treatment of glecaprevir and pibrentasvir in three Japanese patients with HIV and genotype 3 HCV coinfection as well as hemophilia. Glecaprevir and pibrentasvir treatment is safe and effective for Japanese patients with genotype 3 HCV and HIV coinfection.

Full-text article
Download PDF: https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_1856-18/_pdf/-char/en